Global Patau Syndrome Market – Industry Trends and Forecast to 2029

Patau Syndrome Market Analysis and Size

Patau syndrome is one of the least common and most severe condition of the viable autosomal trisomies. The median survival of the patients is less than 3 days. Patau syndrome affects around 1 in every 5,000 births. In addition to this, the risk of having a baby with this syndrome rises with the mother's age. More than 9 out of 10 children born with patau syndrome die during the first year. With regards to its diagnosis, cytogenetic analysis is an essential step in the prenatal diagnosis of the syndrome. It has been witnessed that patients often have low muscle tone that makes them appear very flexible but they lack strength because of this weakness combined with weak bones that leads to frequent fractures.

Data Bridge Market Research analyses a growth rate in the global patau syndrome market in the forecast period 2022-2029. The expected CAGR of global patau syndrome market tend to be around 25% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Patau Syndrome Market Scope and Segmentation

Market Definition

Patau syndrome is a rare genetic disorder that occurs when there are extra chromosomes in the cells of the body. This disorder results from the presence of three, instead of the normal two, copies of chromosome 13 (trisomy). This syndrome includes symptoms such as intellectual disabilities or developmental delays, heart defects, neurological disorders such as seizures, or hyperactivity problems that affect behavior or learning ability among others.

Global Patau Syndrome Market Dynamics

Drivers

• Increasing Prevalence of Patau Syndrome

The rising incidence of patau syndrome is boosting the growth of the market. Patau's syndrome affects about 1 in every 5,000 births. With the passing age, the risk of having a baby with the syndrome increases. More than 9 out of 10 children born with patau syndrome die during the first year. Around 1 in 10 babies witnessing less severe forms of the syndrome, such as partial or mosaic trisomy 13, live for more than a year. Thus, it acts as a major driver in the market growth.

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by the rise in the number of research and development activities. This will provide beneficial opportunities for the global patau syndrome market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.

Opportunities

• Increased Demands of Diagnostic Tests

Different kinds of diagnostic procedures are helping to create opportunities of the global patau Syndrome market. Amniocentesis or chorionic villus sampling (CVS) are available today with regards to this. These are the type of invasive tests to remove a sample of tissue or fluid so that it can be further tested for the presence of the extra copy of chromosome 13. All these factors are contributing in the growth of the market.  

• Increasing Demand of Genetic Testing

The rising demand of genetic testing leads to the market expansion globally. Genetic testing is widely used to help parents plan for future pregnancies. The test results will lead to a more accurate assessment of the likelihood of the syndrome affecting future pregnancies.

Restraints/Challenges

• Lack of Awareness

The sales of potential products are not succeeding much due to the lack of awareness of the syndrome. Though effective treatments are available, but beliefs, poor inadequate communication between clinicians and patients, treatment adherence are the factors impeding the market growth.

• High Cost

The huge expenditure that is associated with the treatment processes hamper the market growth. Numerous market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This global patau syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global patau syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Patau Syndrome Market Scope

The global patau syndrome market is segmented on the basis of treatment, diagnosis, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Ultrasounds
• Cell Free DNA Screening
• Pregnancy Associated Plasma Protein A Screening

Treatment

• Surgery
• Therapies

End-User

• Hospitals
• Research Institutes
• Specialty Clinics

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Global Patau Syndrome Market Regional Analysis/Insights

The global patau syndrome market is analyzed and market size insights and trends are provided by treatment, diagnosis, distribution channel and end-user as referenced above.

The major countries covered in the global patau syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America is dominating the market in the forecast period due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure contributes in raising the significant growth of the market.

Asia-Pacific is considered to have the most lucrative period due to increased new research and developments on patau syndrome market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Patau Syndrome Market Share Analysis

The global patau syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global patau syndrome market

Key players operating in the global patau syndrome market include:

• Centogene N.V. (Germany)
• Eurofins Discovery (Luxembourg)
• Hoffmann-La Roche Ltd. (Switzerland)
• Invitae Corporation (U.S.)
• LLumina Inc (U.S.)
• Natera Inc (U.S.)
• PerkinElmer Inc (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Eurofins LifeCodexx GmbH (Germany)
• Ravgen (U.S.)

SKU-56198